|Year : 2019 | Volume
| Issue : 1 | Page : 41-47
Efficacy of predefined homoeopathic medicines in the treatment of warts: Study protocol of double blind randomised placebo controlled trial
Central Council for Research in Homoeopathy
Director General, Central Council for Research in Homoeopathy, New Delhi, India
|Date of Submission||06-Mar-2019|
|Date of Acceptance||07-Mar-2019|
|Date of Web Publication||29-Mar-2019|
Central Council for Research in Homoeopathy
Director General, Central Council for Research in Homoeopathy, New Delhi
Source of Support: None, Conflict of Interest: None
Background and Objectives: The literature cites a large number of homoeopathic medicines for the treatment of warts. Studies on warts are based on experiences of individual practitioners and do not give specific factors, which are responsible for making a successful prescription for the treatment of warts. The present study was designed as a multicentric randomised, double-blind, placebo-controlled trial to evaluate response to homoeopathic treatment for the disappearance or resolution of warts and to validate the symptoms of the pre-identified 09 drugs (Antimonium crudum, Calcarea carbonicum, Causticum, Dulcamara, Natrum muriaticum, Nitric acidicum, Ruta graveolens, Sulphur and Thuja occidentalis) on clinical outcome in warts. Materials and Methods: The study would be conducted at eight centres of the Central Council for Research in Homoeopathy, where patients requiring any of the predefined medicines for warts would be randomised to Homoeopathy or placebo group using a computer-generated randomisation chart. The selected medicine would be prescribed first in 6C potency and dosage and subsequent potency as per the requirement of the case. Outcome is based on the percentage of warts completely disappeared assessed fortnightly for 6 months. Discussion: The study intends to combine randomised controlled trial with validation of symptoms of the pre-identified drugs in warts. The symptoms of verum group in each case successfully treated would be compared with that in the control group. The study would aid in assessing treatment efficacy and identifying the symptomatology on the basis of which successful prescriptions have been made.
Keywords: Prognostic factor research, Randomised controlled trial, Symptom validation, Warts
|How to cite this article:|
Central Council for Research in Homoeopathy. Efficacy of predefined homoeopathic medicines in the treatment of warts: Study protocol of double blind randomised placebo controlled trial. Indian J Res Homoeopathy 2019;13:41-7
|How to cite this URL:|
Central Council for Research in Homoeopathy. Efficacy of predefined homoeopathic medicines in the treatment of warts: Study protocol of double blind randomised placebo controlled trial. Indian J Res Homoeopathy [serial online] 2019 [cited 2021 Jul 28];13:41-7. Available from: https://www.ijrh.org/text.asp?2019/13/1/41/255264
| Introduction|| |
Warts are common dermatological disorders for which patients frequently seek homoeopathic treatment. In an observational study, results of Thuja occidentalis in verruca vulgaris, verruca plana and verruca plantaris and effect of Ruta graveolens, Calcarea carbonicum, Antimonium crudum, Causticum, Nitric acid, Natrum muriaticum and Opium on different types of warts have been reported. In a double-blind, placebo-controlled clinical trial from 1995 to 1997, the effectiveness of Ruta, Nitric acid, Dulcamara, Causticum and Thuja on different types of warts has been reported. However, two randomised, double-blind, placebo-controlled clinical trials showed no apparent difference between the effect of homoeopathic therapy and placebo in the treatment of warts on hands in children and plantar warts. A recent study on 200 patients reported that, in 88% of cases, remission started within 1 month and complete remission was seen by 3 months.
In Homoeopathy, warts are classified under one-sided disease, i.e. diseases which have very few expressions in terms of symptoms. Under this, it is further categorised under external-local maladies. Warts are recognised as an expression of sycotic miasm in homoeopathic philosophy. Although warts are local diseases, they are treated with internal remedy, based on comprehensive understanding of the patient. The literature cites a large number of homoeopathic medicines for the treatment of warts. Identifying a correct remedy which can correct this internal dyscrasia is a challenge for a routine prescriber.
All the reported studies are unicentric based on experiences of individual practitioners and do not give specific factors, which are responsible for a successful prescription for the treatment of warts.
The Central Council for Research in Homoeopathy (CCRH) aims to undertake research that can be translated into a successful clinical practice. With this background, the present study has been designed as a multicentric randomised, double-blind, placebo-controlled trial to evaluate response to homoeopathic treatment for disappearance or resolution of warts and to validate the symptoms of the pre-identified nine drugs on clinical outcome in warts.
The study protocol is in accordance with the Helsinki declaration on human experimentation. Requisite clearance of the Ethical Committee and Scientific Advisory Committee of CCRH had been obtained before undertaking the study. The ethical approval of the study had been obtained from the Ethical Committee of the Council vide letter no: 1-3/2017-18/ CCRH/TECH/CR/WARTS/1372, dated 24.8.17. The trial is registered with the Clinical Trials Registry of India (CTRI), namely CTRI/2018/12/016672 (registered on: 14/12/2018).
To evaluate response to homoeopathic treatment for disappearance or resolution of warts.
To validate the symptoms of the following pre-identified nine drugs on the successful clinical outcome on warts:
- Antimonium crudum
- Calcarea carbonicum
- Natrum muriaticum
- Nitric acidicum
- Ruta graveolens
- Thuja occidentalis.
| Materials and Methods|| |
The study shall be conducted at different centres of the CCRH located at Agartala, Gudivada, Jaipur, Kolkata, Kottayam, Mumbai, Noida and Puri. The study will be conducted in special dermatology clinics in these research centres. The dermatology clinics are managed by trained homoeopathic practitioners with research experience. The clinics provide routine outpatient department (OPD) care to patients suffering from dermatological disorders using homoeopathic medicines only.
Patients are eligible if they are in the age group of 18–65 years, of either gender, presenting with cutaneous warts. Patients with anogenital or plantar warts would however, be excluded from the study. Patients with bowenoid papulosis, focal epithelial hyperplasia or seborrhoeic keratosis, past history of skin cancer, having undergone treatment with immune-modulating oral medications such as corticosteroids in the past 4 weeks, patients already on homoeopathic treatment for any disease condition, self-reporting cases of HIV, pregnant and lactating women or those with advance disease of vital organs would be excluded from the study.
In all the patients who give consent for participation and fulfil the inclusion criteria, a detailed case taking would be done. Indicated homoeopathic medicine as per symptom similarity would be identified on the basis of the totality of symptoms. Only cases corresponding to the above mentioned pre-identified homoeopathic medicines will be enrolled in the study and randomised. The cases not falling in the above mentioned drug list will not be enrolled in the study. They would be provided standard treatment in the dermatology OPD, and their data will be maintained separately from the study data.
Randomisation and group allocation
Cases enrolled in the study would be randomised into two groups as follows: Groups A and B for each drug with a 1:1 allocation based on computer-based SPSS software. The enrolment number of the patients will be used for the purpose for randomisation and will be maintained for all follow-up visits. Allocation will be concealed till the primary end point is analysed. The allocation codes will be kept with the Principal investigator (PI) and co-investigator (Co-I) at the CCRH headquarters. The randomisation chart allocating patients to the two groups will be sent to the study site along with the study medicines. One group will be administered active drug and the other will be placebo.
The study will be a double-blind study, where the investigators at the study sites and the patients will be kept blind about the group allocation. Un-blinding or breaking of the randomisation codes will be done by the study PI at the headquarters after the study has been completed and the database is frozen. The statistician analysing the data will also be kept blind of the allocation of the groups while analysing the data.
Intervention and follow-up
The drugs identified for the trial shall be procured from a Good Manufacturing Practices (GMP)-compliant pharmaceutical firm. 83.1%v/v ethyl alcohol (used as a vehicle to prepare homoeopathic medicines) will be used as placebo. The placebo will be dispensed in sugar globules of standard size 30 identical to the verum in appearance and taste.
The selected medicine would be initially prescribed in 6C potency at the start of the treatment. Dosage schedule will be as per the requirement of the case. During the period of the study, the potency would be raised sequentially as per the need of the case, in pursuance with the homoeopathic principles. Cases would be followed up at fortnightly interval till complete disappearance of all warts or for 6 months, whichever is earlier. At each follow-up, an assessment would be made of change in the number and size of warts, and any change in associated symptoms. Digital photograph of the site of warts would be made taking into consideration that identity and privacy of the patient is not compromised at any stage.
The participant timeline for each patient is given in [Table 1].
The treatment will be discontinued and patients will be withdrawn early due to non-compliance to treatment or in case of appearance of any adverse drug event.
In the study there are 09 pre-identified drugs and 60 cases will be enrolled at each centre which will be randomized into two groups (30 in drug and 30 in placebo group). As there are 08 study centers, the total sample size for the study will be 480 cases.
Outcome would be the percentage of warts completely disappeared i.e. the number of warts disappeared.
Data recording and analysis
Data of all cases will be maintained by the PI and the Co-I and will be added in a pre-designed master chart. The case record and follow-up formats have been designed with an intent to capture all symptoms associated with warts relating to the pre-specified drugs, with due consideration to the principles of homoeopathic case taking. There are no leading questions pointing to a specific medicine or group of medicines, yet a broad framework with general questions has been added to ensure that the case is completed in all possible aspects, i.e. both general and particular symptoms.
The copy of complete records of the cases will be sent to the PI at the CCRH headquarters after completion of 6-month follow-up of the case in the study. The master chart would be sent to the CCRH headquarters at the end of the study period.
The study outcome will be analysed according to parametric test for continuous data and non-parametric test for ordinal data. Baseline comparison would be considered for evaluating the randomisation effect. All the statistical results would be reported in 95% confidence interval with confidence level alpha (α) = 0.05. Stratified analysis of the variables potentially associated with healing of warts, namely number, type of warts, pain and age of warts, will be done.
Validation of symptoms would be as per the methods described under prognostic factor research for cases treated successfully by homoeopathic medicines.
| Discussion|| |
Warts are frequently considered a one-sided disease with lack of symptoms, and therefore constitutional makeup and other individual characteristics are required for prescription. There has been a long-term experience of homoeopaths that warts disappear when well-indicated medicines covering general and particular symptoms are taken care of during prescription. Therefore, this protocol is designed to prescribe in a similar manner using pre-defined homoeopathic medicines while taking into consideration the basic principles of Homoeopathy; only patients requiring any of the study medicines are included and randomised into treatment and control groups.
The protocol has been developed as per the SPIRIT guidelines and shall generate data that can be reported as per the CONSORT guidelines and RedHot supplement for reporting randomised trials of Homoeopathy. For this study, the drugs were identified on the basis of a literature review and most frequently used in the studies reported. The symptoms related to warts, in particular, and skin complaints, in general, have been identified for validation which would be conducted after the analysis of cases on quantifiable parameters to ascertain the efficacy of treatment.
It has been identified that the best way to assess a causal relationship between cure and medicine is the randomised controlled trial (RCT), but this method is not suited for individual cases. Homoeopathy has a unique opportunity to develop its own scientific identity in achieving evidence-based personalised medicine, whereas RCT evidence fails to serve the needs of the individual patient. We can use accepted scientific methods derived from diagnostic research.
An interesting aspect of Homoeopathy is that the prescription is ‘personalised:’ it fits the patient as a whole, not only the diagnosis. As individualised medicine is the essence of Homoeopathy and a trending topic in medical research, we should focus more on ‘personalised’ research, on validating the symptoms that indicate homoeopathic medicines. This is also an answer to the main problem of RCT evidence: it is not personalised. This recent demand for personalised research besides RCT is an excellent opportunity to favour other methods of evidence-based medicine to improve the knowledge in homoeopathic Materia Medica and Repertories. We can compare the homoeopathic prognostic process with the conventional diagnostic process and use research methods that are common in diagnostic research.
This study intends to combine both the approaches, where the symptomatology in individual cases would be assessed and compared with those in the control group, to not only identify and quantify the efficacy, but also to identify the symptomatology on the basis of which successful prescriptions have been made.
RCTs on warts will ensure that the evident results in terms of disappearance of warts are attributable neither to the self-limiting nature of the condition nor to placebo effect. Subsequently, the prescribing symptomatology would be validated.
However, such a strategy will be able to derive statistics if sufficient number of cases under each drug vis-a-vis control group are generated. This will further help the profession to draw meaningful symptomatic data to make clinical practice easier by using successful research outcome.
Scientific Advisor: Raj K. Manchanda1
Study Concept & Design: Anil Khurana2, Renu Mittal3
Protocol Drafting: Renu Mittal, Gufrana Kamal6
Drafting of Manuscript: Divya Taneja4, Neha Kalra5
Review of Manuscript: Anil Khurana, Renu Mittal
- Director General, CCRH
- Deputy Director General, CCRH
- Research Officer (H)/ Scientist – 3, CCRH
- Research Officer (H)/ Scientist – 2, CCRH
- Senior Research Fellow, CCRH
- Ex. Senior Research Fellow, CCRH
Financial support and sponsorship
The study is fully funded by Central Council for Research in Homoeopathy.
Conflicts of interest
| References|| |
Gupta R, Bhardwaj OP, Manchanda RK. Homoeopathy in the treatment of warts. Br Homeopath J 1991;80:108-11.
Kainz JT, Kozel G, Haidvogl M, Smolle J. Homoeopathic versus placebo therapy of children with warts on the hands: A randomized, double-blind clinical trial. Dermatology 1996;193:318-20.
Labrecque M, Audet D, Latulippe LG, Drouin J. Homeopathic treatment of plantar warts. CMAJ 1992;146(10):1749-53.
Shraddhamayananda S. Healing of skin warts with ultradiluted homeopathic medicines – A study in 200 cases. Clin Res Dermatol Open Access 2017;4(5):1-4.
Oza PM. Homeopathic management of warts. Indian J Drugs Dermatol 2016;2(1):45-7.
World Medical Association. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013;10(20):2191-4.
Rutten AL. Improving homeopathic practice using Bayes’ theorem and likelihood ratio. J Altern Med Res 2009;1(1):1-18.
Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ 2013;346:e7586.
Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
Dean ME, Coulter MK, Fisher P, Jobst KA, Walach H. Reporting data on homeopathic treatments (RedHot): A supplement to CONSORT. J Altern Complement Med 2007;13(1):19-23.
Rutten L. Prognostic factor research in homoeopathy. Indian J Res Homoeopath 2016;10(1):59-65.
Rutten L, Manchanda RK. Homoeopathy: Discussion on scientific validation. Indian J Res Homoeopath 2016;10(1):66-74.
|This article has been cited by|
||A Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Individualized Homeopathic Medicines for Cutaneous Warts
| ||Samit Dey,Shifa Hashmi,Sangita Saha,Mahakas Mandal,Abdur Rahaman Shaikh,Ekta Agrawal,Priyanka Ghosh,Nisha Sehrawat,Munmun Koley,Subhranil Saha |
| ||Homeopathy. 2021; |
|[Pubmed] | [DOI]|